Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials

Published 2015 View Full Article

Authors

Keywords

Journal

ONCOLOGIST

Volume 20, Issue 4, Pages 337-343

Publisher

Alphamed Press

Online

2015-03-03

DOI

10.1634/theoncologist.2014-0334

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

ONCOLOGIST

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find the ideal target journal for your manuscript

Ask a Question. Answer a Question.